Braskem SA (BAK) Stock

Braskem (BAK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Braskem S.A.'s strategies to lower emissions and develop sustainable chemicals are likely to attract significant interest from ESG investors, enhancing stock demand. The company's asset optimization initiatives and transactions, such as the 2024 asset sale to Solví and GRI, are expected to positively impact financial statements. Investments in research and development, including a new Renewable Innovation Center in Massachusetts, are anticipated to drive innovation and free cash flow margin growth.

The heavy selling pressure might have exhausted for Braskem (BAK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Brazil's government and several of its largest commercial banks are working on a plan to speed the divestment of engineering group Novonor's majority stake in Braskem , Latin America's largest petrochemical company, according to six people familiar with the talks.

PHILADELPHIA--(BUSINESS WIRE)--The Philadelphia Eagles and Braskem, (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK) the largest polyolefins producer in the Americas, as well as a global market leader and pioneer producer of biopolymers on an industrial scale, have enhanced their partnership with the launch of their new STEM education program, Tackling STEM, for the 2024-2025 academic school year. Tackling STEM is an education program that delivers free digital and hands-on interactive S.

Braskem S.A. (NYSE:BAK ) Q3 2024 Earnings Conference Call November 7, 2024 9:00 AM ET Company Participants Rosana Avolio - IR, Strategic Planning & Corporate Market Intelligence Director Roberto Bischoff - CEO Pedro Freitas - CFO Conference Call Participants Rodrigo Almeida - Santander Vicente Falanga - Bradesco BBI Tasso Vasconcellos - UBS Gabriel Barra - Citi Pedro Soares - BTG Pactual Leonardo Marcondes - Bank of America Regis Cardoso - XP, Inc. Operator Good morning and thank you for waiting.

Highest quarterly Recurring EBITDA since 2Q22 SÃO PAULO, Nov. 7, 2024 /PRNewswire/ --  BRASKEM S.A. (B3: BRKM3, BRKM5 and BRKM6; NYSE: BAK; LATIBEX: XBRK), the largest resin producer in the Americas and the world's leading biopolymers producer, presents its 3Q24 Earnings Release.

I recommend buying Braskem shares post-2Q24 results, which showed operational improvement despite missing market expectations and ongoing financial challenges. BAK's revenue remained stable at $3.65 billion, with excellent cost control leading to a 9% recurring EBITDA margin. Valuation is attractive with a potential 33.8% appreciation, trading at 6.5x EV/EBITDA against an industry average of 8.7x.

The average of price targets set by Wall Street analysts indicates a potential upside of 46.2% in Braskem (BAK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.